Description:
Incyte Corporation (INCY), based in Wilmington, Delaware, is a leading biopharmaceutical company focused on developing innovative therapies primarily for oncology and other serious diseases. Established in 1991, Incyte's flagship product, Jakafi, has garnered significant market success for the treatment of myelofibrosis and polycythemia vera, while the company continues to expand its promising pipeline of drug candidates aimed at various malignancies. Incyte's dedication to precision medicine and active collaborations underscores its strategic approach to addressing critical unmet medical needs, reinforcing its influential position in the biopharmaceutical sector. With a strong emphasis on scientific advancement and enhancing patient care, Incyte is well-positioned for continued growth and impact in the healthcare industry.
Address:
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, UNITED STATES, 19803
Fiscal year end:
December
Market capitalization:
$21 Billion
Dividend per share:
$0.00
How much was you spent on shares:
$1,000
How much will you earn in
10 years:
-9%
How much will you get:
$911
Prices dates:
31-12-2015: $108.45 and 31-12-2025: $98.77